Tau protein aggregation represents a defining pathological feature of multiple neurodegenerative diseases, collectively termed tauopathies. However, the same tau protein can adopt distinct conformations (termed "strains" or "conformers") that correlate with specific clinical phenotypes. Understanding tau strain diversity and the mechanism of conformational templating is crucial for developing strain-specific diagnostics and therapies[1][2].
Tau strains refer to distinct misfolded conformations of the tau protein that exhibit different biochemical properties, propagation behaviors, and clinical manifestations. These strains are self-perpetuating through a process called conformational templating, where pathological tau can induce normal tau to adopt the same misfolded structure[3][4]. This concept, derived from prion biology, has revolutionized our understanding of protein misfolding disorders and their classification.
The recognition that identical proteins can adopt multiple distinct disease-causing conformations has profound implications for disease classification, biomarker development, and therapeutic targeting. Unlike traditional classification based solely on clinical presentation, strain-based classification reflects the underlying molecular pathology and may better predict disease progression and treatment response[5].
The tauopathies represent a heterogeneous group of neurodegenerative disorders characterized by intracellular tau protein aggregates. While Alzheimer's disease (AD) represents the most common tauopathy, several other conditions exhibit distinct tau pathologies including[6][7]:
Each of these diseases is associated with distinct tau filament structures, suggesting that different conformations of tau underlie the clinical heterogeneity observed in tauopathies[8]. The development of cryo-electron microscopy (cryo-EM) has enabled unprecedented visualization of these strain-specific structural differences.
Tau filaments are composed of paired helical filaments (PHFs) or straight filaments (SFs) depending on the tauopathy type. Cryo-electron microscopy studies have revealed distinct fold architectures that define each strain[12][13]:
The process of conformational templating involves several steps that propagate the strain-specific structure[20][21]:
This templating process allows the strain-specific "information" to be transmitted across neural networks, explaining the characteristic patterns of tau pathology in different tauopathies. The templating efficiency varies by strain, with some propagating more rapidly than others[22].
The structural differences between strains arise from variations in[23][24]:
Progressive Supranuclear Palsy (PSP) represents a paradigmatic example of how distinct tau strains determine disease phenotype. PSP tau strains exhibit unique structural, biochemical, and propagation characteristics that distinguish them from other 4R tauopathies like corticobasal degeneration (CBD) and from mixed 3R/4R tauopathies like Alzheimer's disease[25][26].
Cryo-electron microscopy has revealed that PSP tau filaments possess a distinct three-layer fold architecture that differs fundamentally from both AD and CBD structures[27][28]:
| Feature | PSP | AD | CBD |
|---|---|---|---|
| Core structure | Three-layer fold | C-shaped fold | Hybrid fold |
| Protofilaments | 2 | 2 (asymmetric) | 2-4 |
| Primary isoform | 4R | 3R+4R | 4R |
| Filament width | Narrower | Wider | Variable |
| C-shaped profile | Absent | Present | Partial |
The structural differences between PSP and CBD tau filaments are particularly significant because these diseases present with overlapping clinical features yet require distinct therapeutic approaches[29][30].
PSP exemplifies pure 4R tauopathy, with critical implications for disease mechanisms and therapy[31][32]:
The 4R predominance affects tau function in several ways[33][34]:
PSP tau exhibits characteristic propagation patterns that reflect both the strain structure and the underlying neural circuitry[35][36]:
PSP tau propagation follows distinct circuits[37][38]:
Despite both being 4R tauopathies, PSP and CBD tau strains exhibit distinct molecular characteristics[39][40]:
| Property | PSP | CBD |
|---|---|---|
| Filament uniformity | High | Variable |
| Phosphorylation sites | Specific pattern | Variable pattern |
| Insolubility | High | High |
| Protease resistance | Moderate-high | High |
| Glial pathology | Prominent | Prominent (coiled bodies) |
The molecular differences translate to distinct clinical presentations[41][42]:
Understanding PSP-specific tau strains has critical implications for diagnostic biomarkers[43][44]:
CSF biomarkers:
PET imaging:
Blood biomarkers:
PSP tau strain specificity directly informs therapeutic development[45][46]:
4R-selective therapies:
Propagation blockers:
Stability modifiers:
| Agent | Target | Stage | Notes |
|---|---|---|---|
| Tilavonemab | Anti-tau antibody | Phase 2 | PSP-specific trials |
| AGN-151 | 4R aggregation inhibitor | Preclinical | PSP-targeted |
| MAPT ASO | Exon 10 splicing | Phase 1/2 | Reduces 4R tau |
Current research on PSP tau strains focuses on several key areas[47][48]:
The distinct nature of PSP tau strains underscores the importance of disease-specific therapeutic approaches. As our understanding of PSP tau structure and propagation improves, the prospect of strain-targeted therapies becomes increasingly achievable[49][50].
Different tau strains exhibit distinct biochemical properties that can be used for identification[51][52]:
| Strain Type | Tau Isoforms | Phosphorylation | Insolubility | Protease Resistance | Seeding Activity |
|---|---|---|---|---|---|
| AD PHF | 3R+4R | Hyperphosphorylated | High | Moderate | High |
| PSP | 4R | Moderate | High | High | Moderate |
| CBD | 3R+4R | Variable | High | High | Moderate |
| Pick's | 3R | Moderate | Moderate | Low | Low |
| AGD | 4R | Moderate | Moderate | Moderate | Low |
| CTE | 3R+4R | Variable | High | Moderate | High |
Strains differ in their propagation efficiency and preferred pathways[53][54]:
AD strains: Efficient trans-synaptic spread, widespread distribution following Braak staging pattern, strong seeding activity in experimental assays
PSP strains: Prefer brainstem and basal ganglia pathways, less efficient cortical spread, characteristic subcortical predilection
CBD strains: Asymmetric cortical and subcortical propagation patterns, spread through both short and long-range connections
Pick's strains: More restricted propagation, predominantly frontotemporal networks, limited spread to other regions
CTE strains: Perivascular spread pattern, spread along blood vessels, accumulation at brain interfaces
Multiple approaches enable strain identification[55][56]:
Cryo-EM: Direct visualization of filament structure provides definitive strain identification
Seeding assays: Biochemical tests measuring seeding activity in cell models or biosensor cells
Immunohistochemistry: Strain-specific antibodies recognizing conformational epitopes
Biochemical fractionation: Different solubility patterns enable strain classification
Mass spectrometry: PTM patterns and proteolytic signatures distinguish strains
The tau strain present in a patient's brain largely determines the clinical presentation[57][58]:
Recent research indicates that many tauopathies contain strain mixtures, with multiple conformers present in the same brain[59][60]. These mixtures may explain:
The presence of strain mixtures has important therapeutic implications, as treatments targeting one strain may be less effective against others present simultaneously[61].
Understanding tau strains has significant therapeutic implications[62][63]:
Current research focuses on[67][68]:
Clinical trial design increasingly considers strain-specific factors[69][70]:
| Agent | Strain Target | Trial Phase | Primary Outcome |
|---|---|---|---|
| AADvac1 | AD strains | Phase 2 | Safety, immunogenicity |
| LMTM | Multiple strains | Phase 3 | Cognitive decline |
| Bepranemab | AD strains | Phase 2 | Tau PET reduction |
| Semorinemab | AD strains | Phase 2 | Tau PET reduction |
Tau strains demonstrate remarkable conformational stability during propagation[71][72]:
When multiple strains are present, competitive dynamics emerge[73][74]:
Under certain conditions, strains may undergo structural transitions[75][76]:
Tau strain diversity connects to numerous other topics in neurodegenerative disease research:
The MAPT gene provides the template for tau protein, and specific mutations influence strain formation[77][78]:
Several genetic risk factors modify strain behavior[79][80]:
New approaches promise to advance strain research[81][82]:
Cryo-EM advances: Higher resolution structures revealing finer strain differences
Single-molecule methods: Understanding strain heterogeneity at individual molecule level
Computational modeling: Predicting strain behavior from structural data
Organoid models: Human-derived systems for strain propagation studies
Key areas requiring further investigation include[83][84]:
Tau strain diversity represents a fundamental concept in understanding the heterogeneity of tauopathies. The distinct conformations that tau protein can adopt directly influence disease phenotype, propagation patterns, and potentially therapeutic response. As our ability to detect and characterize tau strains improves, the prospect of strain-specific diagnostics and targeted therapies becomes increasingly feasible.
The field has moved from recognizing that tau pathology exists in different diseases to understanding that fundamentally different molecular structures underlie these conditions. This molecular classification system provides a framework for precision medicine approaches in tauopathies, enabling treatments to be matched to the specific strain present in each patient's brain[85][86].
Future research directions include developing comprehensive strain atlases across tauopathy subtypes, clinical validation of strain-detection biomarkers, development of strain-selective therapeutic agents, and understanding environmental and genetic factors influencing strain emergence.
Fitzpatrick et al. 'Cryo-EM structures of tau filaments from Alzheimer''s disease: 2017'. 2017. ↩︎
'Goedert and Spillantini, Tau pathology in neurodegenerative diseases: 2017'. 2017. ↩︎
'Jucker and Walker, Prion-like propagation of protein aggregation: 2013'. 2013. ↩︎
Frost et al. 'Prion-like mechanisms in neurodegeneration: 2009'. 2009. ↩︎
Sanders et al. 'Tau strains define different tauopathies: 2014'. 2014. ↩︎
Dickson et al. 'Neuropathology of tauopathies: 2012'. 2012. ↩︎
Ferrer et al. 'Tauopathies other than AD: 2008'. 2008. ↩︎
Neumann et al. 'Tauopathies: 2020'. 2020. ↩︎
Schubert et al. 'Tau strain variation: 2018'. 2018. ↩︎
Clavaguera et al. 'Templated propagation of tau aggregates: 2009'. 2009. ↩︎
Arendt et al. 'Tau and clinical phenotype: 2016'. 2016. ↩︎
Fitzpatrick et al. 'Cryo-EM of tau filaments: 2017'. 2017. ↩︎
Falcon et al. 'Tau filaments from CTE: 2018'. 2018. ↩︎
Dickson et al. 'PSP pathology: 2012'. 2012. ↩︎
Neumann et al. 'CBD pathology: 2020'. 2020. ↩︎
McKee et al. 'CTE pathology: 2013'. 2013. ↩︎
'Jucker and Walker, Self-propagation of protein aggregates: 2013'. 2013. ↩︎
Sanders et al. 'Tau strain propagation: 2014'. 2014. ↩︎
Sawaya et al. 'Amyloid protein structures: 2016'. 2016. ↩︎
Fitzpatrick et al. 'Tau filament structures: 2017'. 2017. ↩︎
Schofield et al. 'Tau strains in PSP: 2019'. 2019. ↩︎
Williams et al. 'PSP tau pathology: 2017'. 2017. ↩︎
Fitzpatrick et al. 'Cryo-EM of PSP tau filaments: 2021'. 2021. ↩︎
Shi et al. 'PSP tau structure: 2021'. 2021. ↩︎
Dickson et al. 'PSP and CBD differential pathology: 2019'. 2019. ↩︎
Sergeant et al. '4R tau in PSP: 2005'. 2005. ↩︎
Goedert et al. 'Tau isoforms in disease: 2010'. 2010. ↩︎
Saito et al. 'PSP propagation patterns: 2003'. 2003. ↩︎
Kfoury et al. 'Trans-synaptic tau spread: 2012'. 2012. ↩︎
Taniguchi-Watanabe et al. 'PSP vs CBD tau: 2016'. 2016. ↩︎
Ferrer et al. 'CBD tau morphology: 2019'. 2019. ↩︎
Respondek et al. 'PSP clinical phenotypes: 2013'. 2013. ↩︎
Constantinescu et al. 'PSP biomarkers: 2019'. 2019. ↩︎
Bendlin et al. 'Tau PET in PSP: 2020'. 2020. ↩︎
Höllerhage et al. 'PSP therapeutic strategies: 2021'. 2021. ↩︎
Arnerić et al. 'PSP research priorities: 2020'. 2020. ↩︎
Pollock et al. 'Future directions in PSP: 2021'. 2021. ↩︎
Valasani et al. 'Precision therapy for PSP: 2022'. 2022. ↩︎
Hyman et al. 'Progression of neurodegeneration: 2014'. 2014. ↩︎
'Mandelkow and Mandelkow, Tau in physiology and pathology: 2012'. 2012. ↩︎
Liu et al. 'Tau propagation along circuits: 2012'. 2012. ↩︎
Brettschneider et al. 'Spreading of pathology: 2015'. 2015. ↩︎
Saijo et al. 'Tau seeding assays: 2017'. 2017. ↩︎
Schubert et al. 'Strain detection methods: 2018'. 2018. ↩︎
Gómez-Isla et al. 'Clinical-pathological correlations: 1997'. 1997. ↩︎
Litvan et al. 'PSP clinical features: 2003'. 2003. ↩︎
Spina et al. 'Tau strain mixtures: 2017'. 2017. ↩︎
Dujardin et al. 'Tau strain heterogeneity: 2018'. 2018. ↩︎
Holmes et al. 'Tau-targeted drug development: 2014'. 2014. ↩︎
Davies et al. 'Tau therapeutics: 2016'. 2016. ↩︎
Himmler et al. 'Tau vaccination: 2020'. 2020. ↩︎
Boutajangout et al. 'Anti-tau antibodies: 2011'. 2011. ↩︎
Wischik et al. 'Tau aggregation inhibitors: 2015'. 2015. ↩︎
'Congdon and Sigurdsson, Tau-targeting therapies: 2018'. 2018. ↩︎
Huang et al. 'Clinical trials in tauopathy: 2020'. 2020. ↩︎
Cox et al. 'Strain competition: 2018'. 2018. ↩︎
Lau et al. 'Strain dynamics: 2019'. 2019. ↩︎
Schubert et al. 'Strain transitions: 2018'. 2018. ↩︎
Stöhr et al. 'Strain adaptation: 2018'. 2018. ↩︎
Baker et al. 'MAPT mutations: 2000'. 2000. ↩︎
Rademakers et al. 'MAPT in tauopathies: 2004'. 2004. ↩︎
Liu et al. 'APOE and tau: 2017'. 2017. ↩︎
'Kowalski and Mulle, APOE and tau propagation: 2015'. 2015. ↩︎
Mathys et al. 'Single-cell analysis: 2019'. 2019. ↩︎
Weyn-Vanhentenryck et al. 'Advanced imaging: 2018'. 2018. ↩︎
Medina et al. 'Tau-based therapeutics: 2018'. 2018. ↩︎
Valasani et al. 'Precision tauopathy therapy: 2019'. 2019. ↩︎